2025-02-08 - Analysis Report
## Johnson & Johnson (JNJ) Stock Performance Analysis

**0) Executive Summary:**

Johnson & Johnson (JNJ), a multinational healthcare company, has significantly underperformed the S&P 500 (VOO) over the analyzed period. While exhibiting relatively stable profitability, its return lagged considerably behind the market benchmark, suggesting a need for further investigation into its growth prospects and risk profile. Recent price movements indicate some short-term upward momentum, but longer-term performance is concerning.


**1) Performance Comparison & Alpha/Beta Analysis:**

Johnson & Johnson's cumulative return (30.78%) is substantially lower than the S&P 500's (120.63%). The provided data shows a significant divergence (-89.9%), placing it at the 7.8th percentile of its historical range relative to the S&P 500. This indicates consistent underperformance against the market benchmark.

The Alpha/Beta analysis reveals mixed results.  While CAGR (Compound Annual Growth Rate) fluctuates, Alpha is mostly positive, suggesting outperformance in specific periods, but often small. Beta values consistently hover around 0.0 to 0.7, indicating lower than average volatility relative to the S&P 500, which can be perceived as lower risk but could also suggest less growth potential. The MDD (Maximum Drawdown) shows periods of significant losses, highlighting the inherent risk in JNJ's performance.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 34.0% | 0.2% | 6.0% | -0.1 | 278.1 |
| 2016-2018  | 12.0% | 10.8% | -7.0% | 0.0 | 263.9 |
| 2017-2019  | 21.0% | 10.8% | -9.0% | 0.7 | 306.7 |
| 2018-2020  | 12.0% | 10.8% | -16.0% | 0.4 | 339.9 |
| 2019-2021  | 28.0% | 7.9% | -43.0% | 0.4 | 378.7 |
| 2020-2022  | 17.0% | 7.9% | 9.0% | 0.4 | 401.4 |
| 2021-2023  | -11.0% | 6.9% | -34.0% | 0.4 | 366.9 |
| 2022-2024  | -25.0% | 8.0% | -58.0% | 0.3 | 349.3 |
| 2023-2025  | -8.0% | 8.0% | -69.0% | 0.3 | 370.8 |


**2) Recent Price Movement:**

* **Closing Price:** 153.51
* **Last Market Price:** 153.98
* **5-Day Moving Average:** 153.14
* **20-Day Moving Average:** 148.66
* **60-Day Moving Average:** 148.98

The price is above all three moving averages, suggesting short-term upward momentum.


**3) Technical Indicators & Expected Return:**

* **RSI:** 62.84 (Slightly above neutral; neither overbought nor oversold)
* **PPO:** 0.50 (Positive, indicating bullish momentum)
* **20-Day Relative Divergence Change:** +0.6 (Short-term upward trend)
* **Expected Return (2+ years):** -336.9% (This extremely negative figure strongly suggests significant underperformance against the S&P 500 over the long term if current trends continue.  This needs further investigation as it seems unusually low)

The recent price change (+0.31) is a minor increase and doesn't signal a significant event (no 급반등 or 급하락). The extremely negative expected return warrants a deep dive into the underlying assumptions and data used to calculate this figure.


**4) Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|--------------|
| 2024-10-23 | 1.12 | $22.47 B     |
| 2024-07-25 | 1.95 | $22.45 B     |
| 2024-05-01 | 1.35 | $21.38 B     |
| 2024-02-16 | 1.68 | $21.39 B     |
| 2023-10-27 | 10.32 | $21.35 B     |

EPS is volatile, with a significant spike in Q4 2023.  Revenue is relatively stable.  Further analysis is needed to understand the reasons behind the EPS volatility (one-time events, accounting changes, etc.)


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue     | Profit Margin |
|---------|-------------|---------------|
| 2024-09-30 | $22.47B    | 69.01%        |
| 2024-06-30 | $22.45B    | 69.40%        |
| 2024-03-31 | $21.38B    | 69.55%        |
| 2023-12-31 | $21.39B    | 68.23%        |
| 2023-09-30 | $21.35B    | 69.06%        |

Profit margins are consistently high and relatively stable, suggesting strong operational efficiency.


**Capital and Profitability:**

| Quarter | Equity     | ROE         |
|---------|-------------|-------------|
| 2024-09-30 | $70.16B    | 3.84%       |
| 2024-06-30 | $71.54B    | 6.55%       |
| 2024-03-31 | $70.02B    | 4.65%       |
| 2023-12-31 | $68.77B    | 5.89%       |
| 2023-09-30 | $71.23B    | 36.54%      |

ROE is volatile, with an unusually high value in Q3 2023.  This requires further investigation.


**6) Overall Conclusion:**

Johnson & Johnson displays a concerning pattern of underperformance relative to the S&P 500 despite maintaining strong profitability margins.  While short-term price action shows some positive momentum, the long-term outlook is less clear and warrants careful consideration. The highly negative expected return figure requires validation and a deeper analysis of its underlying assumptions.  Further investigation into the reasons behind the volatility in EPS and ROE, as well as a more detailed analysis of the company's strategic direction and competitive landscape, is crucial before making any investment decisions.  The provided data alone is insufficient to provide a definitive recommendation.
